- Exchange: Frankfurt
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Hemispherx Biopharma Inc+ Add to Watchlist
HXB:GR0.213 EUR 0.005 2.29%
As of 13:50:01 ET on 04/17/2014.
Company Profile for Hemispherx Biopharma Inc (HXB)
Hemispherx Biopharma, Inc. is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen, is undergoing clinical trials for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Hemispherx Biopharma Inc
Key Executives for Hemispherx Biopharma Inc (HXB)
|William A CarterChairman/Pres/CEO/Chief Scientific Ofcr||Thomas K EquelsVice Chair/CFO/Secy/Gen Cnsl|
|David R StrayerChief Medical Ofcr/Medical Dir||Adam PascaleChief Acctg Officer/Controller|
|Wayne S SpringateSenior VP:Operations||Ralph Christopher CavalliVP:Quality Control|